Featured Research

from universities, journals, and other organizations

Benefits of D-penicillamine and trientine for Wilson disease confirmed, according to new study

Date:
March 31, 2011
Source:
European Association for the Study of the Liver
Summary:
Results from a new study have shown both D-penicillamine and trientine continue to be effective treatments, providing positive survival rates in patients with Wilson disease free from a liver transplant.

Results from the first ever European-wide retrospective analysis presented March 31 at the International Liver CongressTM have shown both D-penicillamine and trientine continue to be effective treatments, providing positive survival rates in patients with Wilson disease free from a liver transplant.

Related Articles


Wilson disease is a rare genetic storage disorder in which copper is not excreted by the body effectively, leading to excess copper build up, liver failure and damage to the brain (neurological problems). Worldwide the condition, affects approximately one in 30,000 people. If not treated, Wilson disease can be chronically debilitating and life threatening. While current guidelines recommend the use of chelating agents (D-penicillamine, trientine) as first line therapy of symptomatic patients, optimal treatment regimens are yet to be established.

In this retrospective multicentre cohort study the long-term outcomes of treatment with D-penicillamine and trientine were reviewed in 347 patients with the condition. Changes of medication were common in both groups and resulted in a total of 467 analysed treatments (D-penicillamine, n=326, trientine n=141). Following an average follow-up of 16.5 years, both treatments provided a similar and excellent survival rate and prevented disease progression with the need for liver transplantation in over 98% of patients.

Daniele Prati, EASL's Scientific Committee Member and Press Committee Chairman commented: "Not only does this study show that both treatments are effective options for patients with this rare and often debilitating condition, but it is also encouraging to see how European countries can work together and exchange data which is extremely valuable to guide best practice and evaluate existing treatment regimens. Research on rare liver diseases presents remarkable interest."

"To date, a very limited number of drugs for these conditions are marketed, leaving the majority of rare diseases without any effective treatment. Research into rare diseases and possible cures needs to be strongly encouraged."

Follow-up at 48 months showed that liver deterioration occurred in only 8 out of 515 treatments (D-penicillamine n=4, trientine n=4) while neurological deterioration was less frequent in the D-penicillamine group (7/326 treatments) compared to trientine (12/141, p≤=0.05). Improvements in liver function of symptomatic patients was similar between groups when data were stratified between first and second line treatments, with improvement rates during first line therapy in symptomatic patients of 90.7% for D-penicillamine and 92.6% for trientine.


Story Source:

The above story is based on materials provided by European Association for the Study of the Liver. Note: Materials may be edited for content and length.


Cite This Page:

European Association for the Study of the Liver. "Benefits of D-penicillamine and trientine for Wilson disease confirmed, according to new study." ScienceDaily. ScienceDaily, 31 March 2011. <www.sciencedaily.com/releases/2011/03/110331094607.htm>.
European Association for the Study of the Liver. (2011, March 31). Benefits of D-penicillamine and trientine for Wilson disease confirmed, according to new study. ScienceDaily. Retrieved March 4, 2015 from www.sciencedaily.com/releases/2011/03/110331094607.htm
European Association for the Study of the Liver. "Benefits of D-penicillamine and trientine for Wilson disease confirmed, according to new study." ScienceDaily. www.sciencedaily.com/releases/2011/03/110331094607.htm (accessed March 4, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, March 4, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Adults Only Get The Flu Twice A Decade, Researchers Say

Adults Only Get The Flu Twice A Decade, Researchers Say

Newsy (Mar. 4, 2015) Researchers found adults only get the flu about once every five years. Scientists analyzed how a person&apos;s immunity builds up over time as well. Video provided by Newsy
Powered by NewsLook.com
Mount Everest Has a Poop Problem

Mount Everest Has a Poop Problem

Buzz60 (Mar. 4, 2015) With no bathrooms to use, climbers of Mount Everest have been leaving human waste on the mountain for years, and it&apos;s becoming a health issue. Mike Janela (@mikejanela) has more. Video provided by Buzz60
Powered by NewsLook.com
Obamacare's New Supreme Court Battle

Obamacare's New Supreme Court Battle

Washington Post (Mar. 4, 2015) The Affordable Care Act is facing another challenge at the Supreme Court in King v. Burwell, which deals with subsidies for health insurance. The case could cut out a major provision of Obamacare, causing the law to unravel. Here’s what you need to know about the case. Video provided by Washington Post
Powered by NewsLook.com
Investigation Finds Hurt Workers Suffer More In Some States

Investigation Finds Hurt Workers Suffer More In Some States

Newsy (Mar. 4, 2015) ProPublica and NPR&apos;s joint investigation found drastic cuts to workers compensation benefits and employees&apos; access to those benefits. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins